Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Devineni D, Manitpisitkul P, Vaccaro N, Bernard A, Skee D, Mamidi RN, Tian H, Weiner S, Stieltjes H, Sha S, Rothenberg P. Devineni D, et al. Among authors: mamidi rn. Int J Clin Pharmacol Ther. 2015 Jan;53(1):41-53. doi: 10.5414/CP202157. Int J Clin Pharmacol Ther. 2015. PMID: 25345427 Clinical Trial.
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D, Vaccaro N, Murphy J, Curtin C, Mamidi RN, Weiner S, Wang SS, Ariyawansa J, Stieltjes H, Wajs E, Di Prospero NA, Rothenberg P. Devineni D, et al. Among authors: mamidi rn. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. doi: 10.5414/CP202158. Int J Clin Pharmacol Ther. 2015. PMID: 25407255 Free PMC article. Clinical Trial.
In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
Francke S, Mamidi RN, Solanki B, Scheers E, Jadwin A, Favis R, Devineni D. Francke S, et al. Among authors: mamidi rn. J Clin Pharmacol. 2015 Sep;55(9):1061-72. doi: 10.1002/jcph.506. Epub 2015 May 20. J Clin Pharmacol. 2015. PMID: 25827774
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, Kelley MF, Devineni D, Johnson MD, Lim HK. Mamidi RN, et al. Drug Metab Dispos. 2014 May;42(5):903-16. doi: 10.1124/dmd.113.056440. Epub 2014 Feb 25. Drug Metab Dispos. 2014. PMID: 24568888 Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.
Chatterjee A, Digumarti R, Mamidi RN, Katneni K, Upreti VV, Surath A, Srinivas ML, Uppalapati S, Jiwatani S, Subramaniam S, Srinivas NR. Chatterjee A, et al. Among authors: mamidi rn. J Clin Pharmacol. 2004 Jul;44(7):723-36. doi: 10.1177/0091270004265647. J Clin Pharmacol. 2004. PMID: 15199077 Clinical Trial.
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
De Jonghe S, Proctor J, Vinken P, Feyen B, Wynant I, Marien D, Geys H, Mamidi RN, Johnson MD. De Jonghe S, et al. Among authors: mamidi rn. Chem Biol Interact. 2014 Dec 5;224:1-12. doi: 10.1016/j.cbi.2014.09.018. Epub 2014 Oct 5. Chem Biol Interact. 2014. PMID: 25289773
46 results